News | May 17, 2013

University Hospitals Case Medical Center Clinical Trial Investigates if Denervating Kidney Nerves Reduces Blood pressure

Part of a national study that will enroll 500 patients

May 17, 2013 — Can high blood pressure be safely reduced and controlled by “disconnecting” nerves in the kidneys? That is a question that a new clinical study called Symplicity HTN-3 at University Hospitals (UH) Case Medical Center hopes to answer. 

The study will enroll people who have resistant hypertension, meaning that blood pressure remains extremely high despite taking three or more medications. UH is a clinical site for the five-year national study funded by Medtronic and is one of 90 sites in the nation that will enroll more than 500 people with high blood pressure resistant to medical therapy into the study. 

At UH, the trial is coordinated by the UH Harrington Heart and Vascular Institute and the Clinical Hypertension Program. It will involve a novel multi-disciplinary approach to hypertension treatment using cardiac and kidney specialists. 

Sahil A. Parikh, M.D., an interventional cardiologist in the UH Harrington Heart and Vascular Institute, assistant professor of medicine at Case Western Reserve University School of Medicine and co-principal investigator of the study, said, “This may be a transformative trial if this experimental treatment is found to help patients who have not been able to control their blood pressure and are therefore at extremely high risk for heart attack, stroke, and kidney failure.”

In the Symplicity HTN-3 clinical study, research subjects will be randomly assigned to one of two groups: One-third will continue the best available medical treatment and two-thirds will combine the best available medical treatment with a procedure where participants will have the nerves in their renal arteries disrupted with radio frequency energy that generates heat. The process is called renal denervation.

An earlier study (Symplicity HTN-2), performed in Europe and Australia, found that patients who underwent renal denervation experienced a nearly 30mmHg of systolic blood pressure reduction compared to treatment with medications alone.  (Systolic blood pressure refers to the peak pressure in the arteries and is the top number in a blood pressure reading, which is measured in millimeters of mercury, written as mmHg.) Symplicity HTN-3 will be a much larger trial conducted entirely in the United States.

The denervation of the kidney arteries will be performed in the cardiac catheterization lab by Parikh and colleagues, including Marco Costa, M.D., director, Interventional Cardiovascular Center, UH Harrington Heart and Vascular Institute, and Vikram Kashyap, M.D., co-director, UH Harrington Heart and Vascular Institute and Chief, Division of Vascular Surgery and Endovascular Therapy. Both Costa and Kashyap are professors of medicine at Case Western Reserve University School of Medicine.

“The procedure itself takes about 45 minutes,” said Parikh. “We use low level radio frequency energy to heat the tissue in the renal artery just enough to eliminate the nerves without hurting the arterial wall. Patients generally experience minimal discomfort during the procedure. So far, long-term side effects have been minimal in the patients treated in Europe and Australia.”

Co-principal investigator of the study at UH is Jackson T. Wright, Jr., M.D., Ph.D., director of the Clinical Hypertension Program and director of the WT Dahms, M.D., Clinical Research Unit at UH. “This study will provide the most challenging test of this procedure in the most resistant hypertensive patients who are uncontrolled despite the best therapy available,” said Wright, who is also professor of medicine at Case Western Reserve University and a leading expert in hypertension research.

Hypertension is one of the leading contributors to death from cardiovascular causes in the world. Nearly 1 billion patients worldwide have hypertension requiring therapy.

The study is currently enrolling patients 18 to 80 years old.

For more information: www.uhhospitals.org

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Overlay Init